Modulators of the efficacy and toxicity of drugs in malaria treatment

Trends in Pharmacological Sciences

Volumn 31, Issue 6, 2010, Pages 277-283

  Nzila, Alexis ^a,b   Chilengi, Roma ^a,b  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTESUNATE PLUS MEFLOQUINE; CEFOPERAZONE; CHLOROQUINE; CLAVULANIC ACID; CYCLOSPORIN A; CYTOTOXIC AGENT; DEXVERAPAMIL; FANSIDAR; FOLIC ACID ANTAGONIST; MEFLOQUINE; METHOTREXATE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PRALATREXATE; PROBENECID; PROGUANIL; QUININE; SULBACTAM; SULTAMICILLIN; VALSPODAR; VERAPAMIL;

ADVERSE DRUG REACTION; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CANCER RESISTANCE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; GOUT; HUMAN; IMMUNOPATHOLOGY; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; MALARIA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PENICILLIN RESISTANCE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; DRUG DEVELOPMENT; DRUG EFFECTS; MULTIDRUG RESISTANCE; PROCEDURES;

ANTIMALARIALS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA;

EID: 77953687813     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.03.002     Document Type: Review

References (60)

1. Dondorp A.M., et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 2009, 361:455-467.
2. Nosten F., White N.J. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 2007, 77:181-192.
3. Kokwaro G., et al. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin. Pharmacother. 2007, 8:75-94.
4. Thanh N.X., et al. Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. Trop. Med. Int. Health 2009, 14:504-514.
5. Vivas L., et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop. 2008, 105:222-228.
6. Checkley A.M., Whitty C.J. Artesunate, artemether or quinine in severe Plasmodium falciparum malaria?. Expert Rev. Anti. Infect. Ther. 2007, 5:199-204.
7. Achan J., et al. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ 2009, 339:b2763.
8. Bukirwa H., Orton L. Artesunate plus mefloquine versus mefloquine for treating uncomplicated malaria. Cochrane Database Syst. Rev. 2005, CD004531.
9. David K.P., et al. Atovaquone/proguanil resistance in Africa: a case report. Scand. J. Infect. Dis. 2003, 35:897-898.
10. Mwai L., et al. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob. Agents Chemother. 2009, 53:5069-50738.
11. Musset L., et al. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect. 2006, 8:2599-2604.
12. Nuwaha F. The challenge of chloroquine-resistant malaria in sub-Saharan Africa. Health Policy Plan 2001, 16:1-12.
13. Nzila A. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J. Antimicrob. Chemother. 2006, 57:1043-1054.
14. Basco L.K., Ringwald P. In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob. Agents Chemother. 2003, 47:1391-1394.
15. Ringwald P., et al. In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum. Antimicrob. Agents Chemother. 1999, 43:1525-1527.
16. Sasi P., et al. In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of continued use of 4-Aminoquinolines in East Africa. J. Infect. Dis. 2009, 199:1575-1582.
17. Diasio R.B., Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 1989, 16:215-237.
18. Hanauske A.R., et al. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001, 6:363-373.
19. Wu C.P., et al. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: Evaluation of current strategies. Curr. Mol. Pharmacol. 2008, 1:93-105.
20. Thomas H., Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003, 10:159-165.
21. Robert J., Jarry C. Multidrug resistance reversal agents. J. Med. Chem. 2003, 46:4805-4817.
22. Pusztai L., et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005, 104:682-691.
23. van der Holt B., et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005, 106:2646-2654.
24. Soubeyran P., et al. A phase II study for the evaluation of quinine as a modulator of multidrug resistance in non-Hodgkin's lymphoma. Eur. J. Cancer 2007, 43:53-54.
25. Solary E., et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 2003, 102:1202-1210.
26. Cunningham R.F., et al. Clinical pharmacokinetics of probenecid. Clin. Pharmacokinet. 1981, 6:135-151.
27. Hooijberg J.H., et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999, 59:2532-2535.
28. Fury M.G., et al. A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. Cancer Chemother. Pharmacol. 2005, 57:671-677.
29. Shahid M., et al. Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update. Crit. Rev. Microbiol. 2009, 35:81-108.
30. White A.R., et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J. Antimicrob. Chemother. 2004, 53(suppl. 1). i3-20.
31. Akova M. Sulbactam-containing beta-lactamase inhibitor combinations. Clin. Microbiol. Infect. 2008, 14(Suppl. 1):185-188.
32. Gin A., et al. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev. Anti Infect. Ther. 2007, 5:365-383.
33. Chandra A., et al. Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India. Surg. Infect. (Larchmt) 2008, 9:367-376.
34. Bitonti A.J., et al. Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine. Science 1988, 242:1301-1303.
35. Martin S.K., et al. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 1987, 235:899-901.
36. Egan T.J., Kaschula C.H. Strategies to reverse drug resistance in malaria. Curr. Opin. Infect. Dis. 2007, 20:598-604.
37. Sowunmi A., et al. Comparative efficacy of chloroquine plus chlorpheniramine and halofantrine in acute uncomplicated falciparum malaria in Nigerian children. Trans. R. Soc. Trop. Med. Hyg. 1998, 92:441-445.
38. Sowunmi A., et al. Enhancement of the antimalarial effect of chloroquine by chloropheniramine in vivo. Trop. Med. Int. Health 1998, 3:177-183.
39. Sowunmi A., et al. Comparative efficacy of chloroquine plus chlorpheniramine alone and in a sequential combination with sulfadoxine-pyrimethamine, for the treatment of acute, uncomplicated, falciparum malaria in children. Ann. Trop. Med. Parasitol. 2000, 94:209-217.
40. Sowunmi A., et al. Enhancement of the antimalarial efficacy of amodiaquine by chlorpheniramine in vivo. Mem. Inst. Oswaldo Cruz 2007, 102:417-419.
41. Adovelande J., et al. Synergy between two calcium channel blockers, verapamil and fantofarone (SR33557), in reversing chloroquine resistance in Plasmodium falciparum. Biochem. Pharmacol. 1998, 55:433-440.
42. Ciach M., et al. Reversal of mefloquine and quinine resistance in Plasmodium falciparum with NP30. Antimicrob. Agents Chemother. 2003, 47:2393-2396.
43. Lehane A.M., et al. A verapamil-sensitive chloroquine-associated H+ leak from the digestive vacuole in chloroquine-resistant malaria parasites. J. Cell Sci. 2008, 121:1624-1632.
44. Nzila A., et al. Therapeutic potential of folate uptake inhibition in Plasmodium falciparum. Trends Parasitol. 2004, 20:109-112.
45. Nzila A., et al. Chemosensitization of Plasmodium falciparum by probenecid in vitro. Antimicrob. Agents Chemother. 2003, 47:2108-2112.
46. Nduati E., et al. Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. Parasitol. Res. 2008, 102:1227-1234.
47. Masseno V., et al. In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid. Antimicrob. Agents Chemother. 2009, 53:3131-3134.
48. Sowunmi A., et al. Open randomized study of pyrimethamine-sulphadoxine vs. pyrimethamine-sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children. Trop. Med. Int. Health 2004, 9:606-614.
49. Sowunmi A., et al. Plasmodium falciparum hyperparasitaemia in children. Risk factors, treatment outcomes, and gametocytaemia following treatment. Parasite 2004, 11:317-323.
50. Sowunmi A., et al. Comparative effects of pyrimethamine-sulfadoxine, with and without probenecid, on Plasmodium falciparum gametocytes in children with acute, uncomplicated malaria. Ann. Trop. Med. Parasitol. 2004, 98:873-878.
51. Chabner B.A., et al. Antineoplastic agents. The Pharmacological Basis of Therapeutics 1996, 1233-1287. McGraw-Hill. 9th edn. J.G. Hardman (Ed.).
52. Kalb R.E., et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J. Am. Acad. Dermatol. 2009, 60:824-837.
53. Niehues T., Lankisch P. Recommendations for the use of methotrexate in juvenile idiopathic arthritis. Paediatr. Drugs 2006, 8:347-356.
54. Braun J., Rau R. An update on methotrexate. Curr. Opin. Rheumatol. 2009, 21:216-223.
55. Saif M.W., et al. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin. Investig. Drugs 2009, 18:335-348.
56. Yen-Revollo J.L., et al. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?. Clin. Cancer Res. 2008, 14:8-13.
57. Walzer P.D., et al. Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. Antimicrob. Agents Chemother. 1992, 36:1943-1950.
58. Allegra C.J., et al. Treatment of Pneumocystis carinii pneumonia with trimetrexate in acquired immunodeficiency syndrome (AIDS). Semin. Oncol. 1988, 15(2 Suppl 2):46-49.
59. Kiara S.M., et al. In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation. Antimicrob. Agents Chemother. 2009, 53:3793-3798.
60. Wagner C. Biochemical Role of Folate in Cellular Metabolism. Folate in health and disease 1995, Marcel Dekker, Inc. L.B. Bailey (Ed.).